OR WAIT null SECS
A new therapy (Retaine MGD, OCuSOFT) is available for those who have dry eye syndrome and meibomian gland dysfunction.
Rosenberg, TX-A new therapy (Retaine MGD, OCuSOFT) is available for those who have dry eye syndrome and meibomian gland dysfunction.
The company says it’s the only preservative-free oil-in-water emulsion that moisturizes, lubricates, and protects moderately to severely dry eyes. Using a proprietary cationic process (Novasorb) that binds positively charged ions to the negatively charged ocular surface, the product is designed to prolong corneal contact time to enhance comfort. The hypotonicity of the emulsion adds moisture by lowering the salt concentration of tears, and the lipid component is designed to lubricate and protect the surface of the eye.
“OCuSOFT is extremely excited to offer such a unique solution for dry eye therapy,” said Cynthia L. Barratt, president and chief executive officer of OCuSOFT. “We believe [the emulsion] will become the standard of care for those patients suffering from meibomian gland dysfunction as well as moderate to severe dry eyes.”
The emulsion is packaged in 30 single-dose vials. The company plans to expand the line to include additional artificial tear products.
Special discount pricing is available to physicians dispensing the emulsion from their offices, and patients also may order it directly online at www.retainebrand.com.
For more articles in this issue of Ophthalmology Times eReport, click here.